The emergence of mephedrone and various artificial cathinones has presented worries for lawmakers and regulatory organizations tasked with controlling the proliferation of latest psychoactive substances. The dynamic mother nature of artificial drug manufacturing, coupled with the ability of chemists to change molecular buildings to evade legal cons